Format

Send to

Choose Destination
Respir Med Case Rep. 2017 Jul 14;22:101-105. doi: 10.1016/j.rmcr.2017.07.004. eCollection 2017.

Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.

Author information

1
Pulmonary Department-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
2
Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3
Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.
4
Microdiagnostics, Pathology Private Center, Thessaloniki, Greece.
5
Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece.
6
Pharmacology-Clinical Pharmacology, Department of Clinical, Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
7
Department of Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
8
Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.

Abstract

In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.

KEYWORDS:

Adenocarcinoma; Colitis; Immunotherapy; NSCLC; Nivolumab; Pericarditis; Pneumonitis

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center